The 'boon and bane' of antipsychotic-induced metabolic syndrome.
Venkatasubramanian
G
G
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D020738:Leptin / Q000378:metabolism*; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000378:metabolism; D018696:Neuroprotective Agents / Q000378:metabolism / Q000494:pharmacology; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D012559:Schizophrenia / Q000188:drug therapy; D015430:Weight Gain / Q000187:drug effects*
D014150:Antipsychotic Agents; D020738:Leptin; D018696:Neuroprotective Agents